Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Biphenotypic, Acute 2Patient Preference 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 2fludarabine 2Tacrolimus 2Specimen Handling 2Mycophenolic Acid 2Cyclophosphamide 2Busulfan 2Biopsy 2venetoclax 1veliparib 1tagraxofusp 1decitabine and cedazuridine drug combination 1Whole-Body Irradiation 1Topotecan 1Thiotepa 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Melphalan 1Injections 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Decitabine 1Cytarabine 1Cyclosporine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Myelodysplastic-Myeloproliferative Diseases × decitabine and cedazuridine drug combination × Clear all
NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡